[Microdensitometric study of maturation and fragility of the bone in male patients with cerebral palsy--the effect of long-term administration of 1 alpha-hydroxy vitamin D3 and the value of osteocalcin as a marker of bony growth].
1) We studied bony maturation and fragility in 48 male patients (4-28 years old) with cerebral palsy. They were divided into three groups; group A (drug free, mild motor handicapped), 10 cases, group B (anticonvulsants administrated, mild motor handicapped), 20 cases, group C (anticonvulsants administrated, severe motor handicapped) 18 cases. The indicator of bone mineral content (sigma GS/D) and metacarpal index (MCI) were analyzed by microdensitometric method. A positive correlation between age and sigma GS/D was detected in all groups but a positive correlation between age and MCI was found only in the group B. There was little difference in sigma GS/D and MIC between group A and group B, but those of group C were significantly decreased. These results suggest that increase of bone mineral is related with aging but metacarpal growth is variable, and a lack of daily activity has greater adverse effect on bony metabolism than administration of anticonvulsants. 2) The alterative rates of sigma GS/D (delta sigma GS/D/sigma GS/D/year) and MCI (delta MCI/MCI/year) after 1 alpha-hydroxy vitamin D3 (D3) treatment for 3 years or more were examined in 17 patients with bony atrophy, as compared with normal controls. The alterative rates of sigma GS/D and MCI were elevated in younger patients with D3 treatment but those were decreased in adult patients. Treatment with D3 remarkably increased bony growth in children. 3) In 37 patients, osteocalcin (OC) was measured by radioimmunoassay. OC was elevated in younger patients who were treated with D3.(ABSTRACT TRUNCATED AT 250 WORDS)
Hayashi
Y
Y
Department of Pediatrics, Kochi Medical School.
Araki
K
K
Morioka
N
N
Kurashige
T
T
Shiraishi
T
T
Ogura
H
H
Tani
J
J
D000293:Adolescent; D000328:Adult; D015519:Bone Density / Q000187:drug effects; D001846:Bone Development / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects* / Q000503:physiopathology; D002547:Cerebral Palsy / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D003720:Densitometry; D004341:Drug Evaluation; D006801:Humans; D006887:Hydroxycholecalciferols / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D015675:Osteocalcin / Q000097:blood*
D006887:Hydroxycholecalciferols; D015675:Osteocalcin; C008088:alfacalcidol